Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling

Biochemical Pharmacology

Volumn 77, Issue 3, 2009, Pages 422-432

  Gruenbaum, Lore M ^a   Schwartz, Racheline ^a   Woska Jr , Joseph R ^a   DeLeon, Rodney P ^a   Peet, Gregory W ^a   Warren, Thomas C ^a   Capolino, Alison ^a   Mara, Lisa ^a   Morelock, Maurice M ^a   Shrutkowski, Anthony ^a   Jones, Jessi Wildeson ^a   Pargellis, Christopher A ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

High content imaging; Monocytes; Neutrophils; p38; Protein kinase inhibitor; T cells

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; CYTOKINE; DORAMAPIMOD; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMAGING; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STRESS; T LYMPHOCYTE;

CYTOKINES; HELA CELLS; HUMANS; INFLAMMATION MEDIATORS; MITOGEN-ACTIVATED PROTEIN KINASE 9; NAPHTHALENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRAZOLES; SIGNAL TRANSDUCTION;

EID: 58249135759     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.10.032     Document Type: Article

References (30)

1. Raingeaud J., Gupta S., Rogers J.S., Dickens M., Han J., Ulevitch R.J., et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270 (1995) 7420-7426
2. Ono K., and Han J. The p38 signal transduction pathway activation and function. Cell Signal 12 (2000) 1-13
3. Guo X., Gerl R.E., and Schrader J.W. Defining the involvement of p38α MAPK in the production of anti- and proinflammatory cytokines using an SB203580-resistant form of the kinase. J Biol Chem 278 (2003) 22237-22242
4. Rincon M., Enslen H., Raingeaud J., Recht M., Zapton T., Su M.S., et al. Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J 17 (1998) 2817-2829
5. Berenson L.S., Yang J.F., Sleckman B.P., Murphy T.L., and Murphy K.M. Selective requirement of p38 alpha MAPK in cytokine-dependent, but not antigen receptor-dependent, Th1 responses. J Immunol 176 (2006) 4616-4621
6. Winzen R., Kracht M., Ritter B., Wilhelm A., Chen C.A., Shyu A.B., et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J 18 (1999) 4969-4980
7. Kotlyarov A., Neininger A., Schubert C., Eckert R., Birchmeier C., and Volk H. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat Cell Biol 1 (1999) 94-97
8. Gaestel M. MAPKAP kinases - MKs - two's company, three's a crowd. Nat Rev Mol Cell Biol 7 (2006) 120-130
9. Swantek J.L., Cobb M.H., and Geppert T.D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor-α (TNF-α) translation: glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK. Mol Cell Biol 17 (1997) 6274-6282
10. Ishizuka T., Terada N., Gerwins P., Hamelmann E., Oshiba A., Fanger G.R., et al. Mast cell tumor necrosis factor α production is regulated by MEK kinases. Proc Natl Acad Sci USA 94 (1997) 6358-6363
11. Manning A.M., and Davis R.J. Targeting JNK for therapeutic benefit: from junk to gold?. Nat Rev Drug Discov 2 (2003) 554-565
12. Dinarello C.A. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr Opin Immunol 3 (1991) 941-948
13. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14 (1996) 397-440
14. Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., and Adams J.L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47 (2000) 185-201
15. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
16. Pargellis C., Tong L., Churchill L., Cirillo P., Gilmore T., Graham A.G., et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9 (2002) 268-272
17. Branger J., van den Blink B., Weijer S., Madwed J., Bos C.L., Gupta A., et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168 (2002) 4070-4077
18. Fabian M.A., Biggs W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23 (2005) 329-336
19. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98 (2001) 13681-13686
20. Kuma Y., Sabio G., Bain J., Shapiro N., Marquez R., and Cuenda A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem 280 (2005) 19472-19479
21. Morelock M.M., Pargellis C.A., Graham E.T., Lamarre D., and Jung G. Time-resolved ligand exchange reactions: kinetic models for competitive inhibitors with recombinant human rennin. J Med Chem 38 (1995) 1751-1761
22. Regan J., Breitfelder S., Cirillo P., Gilmore T., Graham A.G., Hickey E., et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem 45 (2002) 2994-3008
23. Regan J., Capolino A., Cirillo P.F., Gilmore T., Graham A.G., Hickey E., et al. Structure-activity relationships of the p38α MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalene-1-yl]urea (BIRB796). J Med Chem 46 (2003) 4676-4686
24. Sullivan J.E., Holdgate G.A., Campbell D., Timms D., Gerhardt S., Breed J., et al. Prevention of MKK6-dependent activation by binding to p38α MAP kinase. Biochemistry 44 (2005) 16475-16490
25. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., and Griswold D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 279 (1996) 1453-1461
26. Godl K., Wissing J., Kurtenbach A., Habenberger P., Blencke S., Gutbrod H., et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 100 (2003) 15434-15439
27. Manning M.M., and Davis R.J. Targeting JNK for therapeutic benefit: from junk to gold?. Nat Rev Drug Discov 2 (2003) 554-565
28. + T cell activation. J Exp Med 195 (2002) 811-823
29. Haddad J.E. VX-745 vertex pharmaceuticals. Curr Opin Invest Drugs 2 (2001) 1070-1076
30. Wadsworth S.A., Cavender D.E., Beers S.A., Lalan P., Schafer P.H., Malloy E.A., et al. RWJ 67657, a potent orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 291 (1999) 680-687